Latest News

March 1st, 2011
Announcing 510(k) Clearance of a New Microfluidic-based IVD Test System, the μTASWakoTM i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment.

Contact: Audrey Long at 877-714-1924


Oct. 2010
New! Quest Diagnostics now offers HCC panel test. This HCC panel test conveniently allows measurement of AFP-L3% and DCP with a single test code: 16222

Contact Us

Clinical Diagnostic Reagents:
diagnostics@wakousa.com

HCC Biomarkers and
μTASWako® i30:
liver@wakousa.com

Phone: 877-714-1924

Certificates

ISO 13485:2003

HCC Biomarkers

FDA 510(k) Cleared
for HCC Risk Assessment

Wako's AFP-L3 and DCP (also known as PIVKA-II) tests are available through major reference labs.
To learn how HCC biomarkers can improve surveillance of HCC:

For Health care professionals

For Laboratories

For Patients

Meetings

DDW 2012
Digestive Disease Week
May 19-22, 2012
San Diego, CA
Booth #2931

Please visit the presentation at
DDW Theater
2:00 PM, Sunday, May 20th
"Up To Date Screening for Hepatocellular Carcinoma:
Adding AFP-L3 and DCP Biomarkers"
By Catherine T. Frenette, M.D.
Medical Director of Liver Transplantation and Hepatocellular Carcinoma Program
The Methodist Hospital, Houston, TX

Clinical Lab Expo 2012
AACC, American Association of Clinical Chemistry
July 15-19, 2012
Los Angeles, CA
Booth #1617

ACG 2012
American College of Gastroenterology
Oct 19-24, 2012
Las Vegas, NV
Booth TBD

TLM 2012
The Liver Meeting
Nov 1-5, 2012
Boston, MA
Booth TBD